Literature DB >> 3937535

Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia.

J Koizumi, H Mabuchi, A Yoshimura, I Michishita, M Takeda, H Itoh, Y Sakai, T Sakai, K Ueda, R Takeda.   

Abstract

Lipoprotein patterns and cholesteryl ester transfer activity (CETA) were examined in 2 patients with familial hyperalphalipoproteinaemia (FHALP). The proband was a healthy 58-year-old Japanese male who had an HDL cholesterol of 7.83 mmol/l (301 mg/dl). His sister's HDL cholesterol was 4.52 mmol/l (174 mg/dl), which suggested that both were homozygous carriers of FHALP. In both subjects HDL showed a high cholesterol/apo A-I ratio and appeared to be a larger-sized particle than normal HDL on agarose gel chromatography. Two of the proband's children showed higher HDL cholesterol levels (1.74 mmol/l, 2.16 mmol/l) than normal, but another 2 children showed normal levels (1.48 mmol/l, 1.40 mmol/l). However, the ratios of HDL cholesterol to total cholesterol and to apo A-I in all children were higher than normal. These data suggest, but do not prove, that all his children were heterozygotes. Apo B levels in all of the family members studied were lower than normal (47-80 mg/dl). Deceased members of the same family had not died from cardiovascular disease. Cholesteryl-ester transfer activity was studied in both patients. When serum or lipoprotein deficient serum (d greater than 1.21) and [3H]cholesteryl ester labelled HDL3 were incubated in the presence of an LCAT inhibitor, there was no evidence of cholesteryl ester transfer from HDL to VLDL and/or LDL, unlike normal subjects. The deficiency of CETA in these patients with FHALP presumably accounted for the increase in particle size and cholesterol enrichment of HDL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937535     DOI: 10.1016/0021-9150(85)90064-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

1.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

Review 2.  New targets for medical treatment of lipid disorders.

Authors:  Margaret E Brousseau; Ernst J Schaefer
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.113

3.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

Review 4.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 5.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 6.  Interaction of lipid transfer protein with plasma lipoproteins and cell membranes.

Authors:  R E Morton
Journal:  Experientia       Date:  1990-06-15

7.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

8.  Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.

Authors:  K Ikewaki; D J Rader; T Sakamoto; M Nishiwaki; N Wakimoto; J R Schaefer; T Ishikawa; T Fairwell; L A Zech; H Nakamura
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Cholesteryl ester transfer protein gene polymorphisms and longevity syndrome.

Authors:  Genovefa Kolovou; Marianna Stamatelatou; Katherine Anagnostopoulou; Peggy Kostakou; Vana Kolovou; Constantinos Mihas; Ioannis Vasiliadis; Olga Diakoumakou; Dimitri P Mikhailidis; Dennis V Cokkinos
Journal:  Open Cardiovasc Med J       Date:  2010-01-29

10.  Structural Plasticity of Cholesteryl Ester Transfer Protein Assists the Lipid Transfer Activity.

Authors:  Venkat R Chirasani; Prasanna D Revanasiddappa; Sanjib Senapati
Journal:  J Biol Chem       Date:  2016-07-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.